Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03401047 · ClinicalTrials.gov registry record · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
A Early Phase 1 study of Polycystic Ovary Syndrome, sponsored by University of Virginia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT03401047: Recruiting Early Phase 1 study of Polycystic Ovary Syndrome, sponsored by University of Virginia.
NCT03401047 is a Early Phase 1 study of Polycystic Ovary Syndrome that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 37 participants, below the 17,257-participant average among 30 other Polycystic Ovary Syndrome trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03401047, a Early Phase 1 study of Polycystic Ovary Syndrome, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if estradiol augmentation of luteinizing hormone (LH) secretion secretion (primary endpoint) and follicle-stimulating hormone (FSH) secretion (secondary endpoint) is reduced in adult women with polycystic ovary syndrome.
Primary Outcome
The estradiol-induced change in 24-hour urinary LH excretion is defined as the 24-hour urinary LH excretion immediately prior to estradiol administration vs. the peak 24-hour urinary LH excretion during estradiol administration.
Conditions Studied
Interventions
- DRUG Estradiol
Study Locations (1)
Virginia
- University of Virginia Clinical Research Unit - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2025-12-01 |
| Phase | Early Phase 1 |
What NCT03401047 shows while recruiting
NCT03401047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 17,257-participant average among 30 other Polycystic Ovary Syndrome trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Polycystic Ovary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Estradiol is the first listed.
NCT03401047 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT03401047 about?
NCT03401047 is a clinical study titled "Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome". The purpose of this study is to determine if estradiol augmentation of luteinizing hormone (LH) secretion secretion (primary endpoint) and follicle-stimulating hormone (FSH) secretion (secondary endpoint) is reduced in adult women with polycystic ovary syndrome.
What is the current status of trial NCT03401047?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 37 participants. The study started on 2017-11-30. Estimated completion is 2025-12-01.
What conditions does trial NCT03401047 study?
This clinical trial studies the following conditions: Polycystic Ovary Syndrome.
What interventions are being tested in trial NCT03401047?
The interventions under investigation include: Estradiol (DRUG).
Who is sponsoring clinical trial NCT03401047?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03401047 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycystic Ovary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03401047's enrollment target sits among peer trials
37 24th of 30 higher than 7 of 30 other Polycystic Ovary Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Polycystic Ovary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?
RECRUITING · Early Phase 1
-
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
RECRUITING · Early Phase 1
-
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
RECRUITING · Early Phase 1
-
Combined Oral Contraceptive Pill and Resistance Starch
RECRUITING · Phase 2
-
The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
RECRUITING · NA
-
Apple Women's Health Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03935984 · 37 participants · Phase 4
Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI